New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (NASDAQ:CMPS) as a recipient of its U.S. healthcare provider training grant program. Through the collaboration, Fluence is developing a new certificate program designed to prepare healthcare providers to deliver high-quality care for patients receiving COMP360 psilocybin treatment, if approved by the U.S. Food and Drug Administration (FDA).

Fluence International, Inc.

COMP360 is an investigational synthetic psilocybin treatment currently being evaluated for treatment-resistant depression. In anticipation of potential FDA approval and subsequent commercial availability, the Post-Approval COMP360 Psilocybin Certificate Program will prepare clinicians with the knowledge and skills required to support patients throughout the COMP360 treatment experience. The program will combine Fluence's experience training thousands of clinicians in psychedelic therapy with Compass Pathways' clinical guidance for COMP360.

The certificate program will progress through three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification. Clinicians will build foundational skills for supporting patients through psychedelic treatment, develop an understanding of psilocybin and the research behind its therapeutic use, and receive COMP360-specific training covering the compound, applicable regulations, patient preparation, treatment administration, and follow-up.

"This is a moment Fluence has been preparing for since our earliest days," said Elizabeth Nielson, PhD, Chief Executive Officer and Co-Founder of Fluence. "Our goal has always been to help clinicians translate rigorous psychedelic research into safe, skilled and evidence-based clinical practice. Working with Compass to prepare providers for the potential introduction of COMP360 allows us to bring together years of clinician education and clinical research training in a program designed for real-world care."

Fluence was a training partner selected by Compass Pathways through a competitive process based on expertise in psychedelic training design, delivery and governance, ability to scale, commitment to access and inclusion, and regulatory alignment.

In addition to training individual clinicians, Fluence supports healthcare organizations preparing and managing clinical workforces at scale. Through its training operations platform, organizations can enroll providers and access real-time data on training progress, completion, competency and credentialing, providing the visibility and documentation needed to develop a consistently trained and verifiably prepared workforce.

To pre-enroll or learn more visit our website.

About Fluence

Fluence builds the human capabilities required for psychedelic and neuroplastogen care. Through evidence-based training, expert instruction, experiential practice and competency assessment, Fluence prepares clinicians to deliver high-quality care and enables organizations to develop competent, consistently trained and verifiably prepared providers. Fluence's programs are grounded in clinical research and designed for the realities and responsibilities of clinical practice. www.fluencetraining.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html

SOURCE Fluence International, Inc.